For research use only.
CAS No. 9007-28-7
Chondroitin sulfate (CS) is a major component of the extracellular matrix (ECM) of many connective tissues, including cartilage, bone, skin, ligaments and tendons. It reduces the IL-1β-induced nuclear factor-kB (NF-κB) translocation in chondrocytes in vitro.
Purity & Quality Control
|Description||Chondroitin sulfate (CS) is a major component of the extracellular matrix (ECM) of many connective tissues, including cartilage, bone, skin, ligaments and tendons. It reduces the IL-1β-induced nuclear factor-kB (NF-κB) translocation in chondrocytes in vitro.|
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04507074||Recruiting||Device: lumbar traction therapy||Low Back Pain|Obesity||Poznan University of Physical Education||January 1 2020||Not Applicable|
|NCT03463499||Active not recruiting||Drug: Hyaluronic Acid and Chondroitin Sulfate||Interstitial Cystitis||Samsung Medical Center||September 22 2017||Not Applicable|
|NCT03827161||Completed||Dietary Supplement: Glucosamine|Other: Placebo||Healthy Subject|Overweight||Fred Hutchinson Cancer Research Center||August 1 2017||Phase 1|
|NCT01856218||Completed||Drug: UX003||Mucopolysaccharidosis Type 7||Ultragenyx Pharmaceutical Inc||November 2013||Phase 1|Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.